- Home
- MOLN vs KFS Comparison
MOLN vs KFS Comparison
Compare MOLN & KFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- KFS
- Stock Information
- Founded
- MOLN 2004
- KFS 1989
- Country
- MOLN Switzerland
- KFS United States
- Employees
- MOLN N/A
- KFS N/A
- Industry
- MOLN
- KFS Property-Casualty Insurers
- Sector
- MOLN
- KFS Finance
- Exchange
- MOLN Nasdaq
- KFS Nasdaq
- Market Cap
- MOLN 195.4M
- KFS 234.2M
- IPO Year
- MOLN 2021
- KFS 1996
- Fundamental
- Price
- MOLN $5.56
- KFS $8.16
- Analyst Decision
- MOLN
- KFS
- Analyst Count
- MOLN 0
- KFS 0
- Target Price
- MOLN N/A
- KFS N/A
- AVG Volume (30 Days)
- MOLN 7.1K
- KFS 59.7K
- Earning Date
- MOLN 03-13-2025
- KFS 03-04-2025
- Dividend Yield
- MOLN N/A
- KFS N/A
- EPS Growth
- MOLN N/A
- KFS N/A
- EPS
- MOLN N/A
- KFS N/A
- Revenue
- MOLN $7,105,397.00
- KFS $108,627,000.00
- Revenue This Year
- MOLN N/A
- KFS N/A
- Revenue Next Year
- MOLN $29.41
- KFS N/A
- P/E Ratio
- MOLN N/A
- KFS N/A
- Revenue Growth
- MOLN N/A
- KFS 2.02
- 52 Week Low
- MOLN $3.32
- KFS $7.60
- 52 Week High
- MOLN $12.70
- KFS $9.58
- Technical
- Relative Strength Index (RSI)
- MOLN 53.39
- KFS 43.16
- Support Level
- MOLN $4.98
- KFS $7.74
- Resistance Level
- MOLN $5.91
- KFS $8.38
- Average True Range (ATR)
- MOLN 0.27
- KFS 0.18
- MACD
- MOLN 0.08
- KFS 0.02
- Stochastic Oscillator
- MOLN 69.45
- KFS 51.22
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.